Produktinformation
- (2R,4S)-4-[(3,5-Bis-trifluoromethylbenzyl)methoxycarbonylamino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester
- (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]methoxycarbonylamino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester
- 1(2H)-Quinolinecarboxylic acid, 4-[[[3,5-bis(trifluoromethyl)phenyl]methyl](methoxycarbonyl)amino]-2-ethyl-3,4-dihydro-6-(trifluoromethyl)-, ethyl ester, (2R,4S)-
- Cp 529414
- ethyl (2R,4S)-4-{[3,5-bis(trifluoromethyl)benzyl](methoxycarbonyl)amino}-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2H)-carboxylate
Torcetrapib is a drug that inhibits the enzyme DPP-IV, which is responsible for the degradation of a protein called DPP-4. Torcetrapib has been shown to improve atherosclerotic lesions in humans and mice by inhibiting DPP-IV, which prevents the destruction of DPP-4. It also increases levels of a protein called IL-2 receptor, which is involved in immune response and inhibition of tumour growth. Torcetrapib has not been shown to be carcinogenic or mutagenic in animal models. Torcetrapib binds to the cytosolic Ca2+ channel and reduces the activity of this channel, inhibiting cellular proliferation and reducing cholesterol levels in cells. Torcetrapib also has low potency against proteins such as IL-2 receptor and cytosolic Ca2+.
Chemische Eigenschaften
Technische Anfrage zu: 3D-FT15754 Torcetrapib
Wenn Sie ein Angebot anfordern oder eine Bestellung aufgeben möchten, legen Sie stattdessen die gewünschten Produkte in Ihren Warenkorb und fordern Sie dann ein Angebot oder eine Bestellung an aus dem Warenkorb. Es ist schneller, billiger und Sie können von den verfügbaren Rabatten und anderen Vorteilen profitieren.
